IN2014CN04482A - - Google Patents
Download PDFInfo
- Publication number
- IN2014CN04482A IN2014CN04482A IN4482CHN2014A IN2014CN04482A IN 2014CN04482 A IN2014CN04482 A IN 2014CN04482A IN 4482CHN2014 A IN4482CHN2014 A IN 4482CHN2014A IN 2014CN04482 A IN2014CN04482 A IN 2014CN04482A
- Authority
- IN
- India
- Prior art keywords
- polypeptide
- integrin
- modified polypeptide
- affinity
- drugs
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 229920001184 polypeptide Polymers 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 102000006495 integrins Human genes 0.000 abstract 2
- 108010044426 integrins Proteins 0.000 abstract 2
- 239000002202 Polyethylene glycol Substances 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 229920001223 polyethylene glycol Polymers 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
- C07K17/04—Peptides being immobilised on, or in, an organic carrier entrapped within the carrier, e.g. gel, hollow fibre
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
- C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011103705299A CN102417540A (zh) | 2011-11-21 | 2011-11-21 | 一种聚乙二醇修饰的整合素阻断剂hm-3及其应用 |
| PCT/CN2012/084788 WO2013075600A1 (zh) | 2011-11-21 | 2012-11-17 | 一种聚乙二醇修饰的整合素阻断剂hm-3及其应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014CN04482A true IN2014CN04482A (zh) | 2015-09-04 |
Family
ID=45942198
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN4482CHN2014 IN2014CN04482A (zh) | 2011-11-21 | 2012-11-17 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20140329759A1 (zh) |
| EP (1) | EP2784093B1 (zh) |
| KR (2) | KR20140096373A (zh) |
| CN (1) | CN102417540A (zh) |
| AU (1) | AU2012343020B2 (zh) |
| IN (1) | IN2014CN04482A (zh) |
| WO (1) | WO2013075600A1 (zh) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102417540A (zh) * | 2011-11-21 | 2012-04-18 | 中国药科大学 | 一种聚乙二醇修饰的整合素阻断剂hm-3及其应用 |
| CN103656615B (zh) * | 2013-12-11 | 2017-01-04 | 南京安吉生物科技有限公司 | 一种hm-3和铂类、紫杉醇类或他滨类药物在制备实体瘤药物中的用途 |
| CN103623394A (zh) * | 2013-12-11 | 2014-03-12 | 南京安吉生物科技有限公司 | 一种peg-hm-3和铂类、紫杉醇类或他滨类药物在制备实体瘤药物中的用途 |
| CN103739673B (zh) * | 2013-12-31 | 2015-08-19 | 浙江元太生物科技有限公司 | 一种聚乙二醇修饰的抑制白介素-6多肽及其应用 |
| CN103739671B (zh) * | 2013-12-31 | 2015-08-26 | 郭向华 | 一种聚乙二醇修饰的抑制核因子-κB多肽及其应用 |
| CN103739669B (zh) * | 2013-12-31 | 2015-08-26 | 浙江元太生物科技有限公司 | 一种抑制白介素-6多肽及其应用 |
| CN103720667B (zh) * | 2014-01-09 | 2016-04-13 | 中国药科大学 | Ap-25多肽冻干粉针制剂及其制备方法和用途 |
| CN103736078B (zh) * | 2014-01-09 | 2017-12-12 | 南京安吉生物科技有限公司 | mPEG‑HM‑3多肽冻干粉针制剂及其制备方法和用途 |
| CN103819542A (zh) * | 2014-02-28 | 2014-05-28 | 中国药科大学 | 一种聚乙二醇修饰及蛋白质融合表达的整合素阻断剂ap-25及其应用 |
| CN104127378A (zh) * | 2014-08-11 | 2014-11-05 | 中国药科大学 | mPEG-SC20K-HM-3多肽注射液及其制备方法和用途 |
| CN105622721A (zh) * | 2015-12-16 | 2016-06-01 | 李斯文 | 一种聚乙二醇修饰的血管生成抑制剂hs-1及其应用 |
| CN105646667A (zh) * | 2016-04-06 | 2016-06-08 | 南京安吉生物科技有限公司 | 聚乙二醇修饰的血管生成抑制剂hm-1及其应用 |
| CN108623693B (zh) * | 2017-03-20 | 2022-03-25 | 徐寒梅 | 一种融合蛋白及其制备方法和其在制备治疗眼科疾病、抗炎、抗肿瘤药物中的应用 |
| CN109503700A (zh) * | 2017-09-14 | 2019-03-22 | 南京安吉生物科技有限公司 | 马来酰亚胺基团修饰的血管生成抑制剂hm-1及其应用 |
| CN107857800B (zh) * | 2017-11-09 | 2020-05-05 | 北京赛升药业股份有限公司 | 一种长效整合素抑制剂及其应用 |
| CN109879969B (zh) * | 2017-12-06 | 2024-04-09 | 天士力生物医药股份有限公司 | 一种hm-3融合蛋白及其应用 |
| CN111855876B (zh) * | 2020-07-10 | 2023-05-02 | 北京赛升药业股份有限公司 | 一种安替安吉肽有关物质的检测方法 |
| CN114230676A (zh) * | 2021-12-22 | 2022-03-25 | 天士力生物医药股份有限公司 | 重组hm-3融合蛋白及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| US6521593B1 (en) * | 1999-02-01 | 2003-02-18 | Childrens Hospital Los Angeles | Methods for inhibiting brain tumor growth |
| EA200500871A1 (ru) * | 2002-11-25 | 2006-04-28 | Атеньюон, Ллк | Пептиды, ингибирующие ангиогенез, миграцию клеток, инвазию клеток и пролиферацию клеток, композиции и их применение |
| CN1314705C (zh) * | 2005-06-03 | 2007-05-09 | 中国药科大学 | 高效抑制血管生成多肽及其制备方法和应用 |
| KR100863060B1 (ko) * | 2006-06-02 | 2008-10-10 | 베이징 선바이오 바이오테크, 코오퍼레이션, 리미티드 | 암 억제 활동을 하는 재조합 단백질, 그 암호화 유전자 및 재조합 단백질을 활성성분으로 포함하는 암치료용 약학적 조성물 |
| CN102145161A (zh) * | 2011-04-07 | 2011-08-10 | 中国药科大学 | 整合素阻断剂在制备治疗肿瘤药物中的应用 |
| CN102178656B (zh) * | 2011-05-12 | 2012-08-22 | 内蒙古奇特生物高科技（集团）有限公司 | Hm-3多肽冻干粉制剂及其制备方法 |
| CN102205110B (zh) * | 2011-05-18 | 2014-03-26 | 中国药科大学 | 整合素阻断剂在制备治疗新生血管性眼病药物中的应用 |
| CN102417540A (zh) * | 2011-11-21 | 2012-04-18 | 中国药科大学 | 一种聚乙二醇修饰的整合素阻断剂hm-3及其应用 |
| CN104127378A (zh) * | 2014-08-11 | 2014-11-05 | 中国药科大学 | mPEG-SC20K-HM-3多肽注射液及其制备方法和用途 |
-
2011
- 2011-11-21 CN CN2011103705299A patent/CN102417540A/zh active Pending
-
2012
- 2012-11-17 KR KR1020147016557A patent/KR20140096373A/ko active Search and Examination
- 2012-11-17 AU AU2012343020A patent/AU2012343020B2/en active Active
- 2012-11-17 KR KR1020197020874A patent/KR102106485B1/ko active IP Right Grant
- 2012-11-17 US US14/359,462 patent/US20140329759A1/en not_active Abandoned
- 2012-11-17 WO PCT/CN2012/084788 patent/WO2013075600A1/zh active Application Filing
- 2012-11-17 IN IN4482CHN2014 patent/IN2014CN04482A/en unknown
- 2012-11-17 EP EP12851929.5A patent/EP2784093B1/en active Active
-
2016
- 2016-10-24 US US15/332,539 patent/US20170100489A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20140096373A (ko) | 2014-08-05 |
| EP2784093B1 (en) | 2019-10-09 |
| AU2012343020A1 (en) | 2014-06-12 |
| US20140329759A1 (en) | 2014-11-06 |
| EP2784093A4 (en) | 2015-08-05 |
| WO2013075600A1 (zh) | 2013-05-30 |
| KR102106485B1 (ko) | 2020-05-04 |
| KR20190090872A (ko) | 2019-08-02 |
| AU2012343020B2 (en) | 2016-05-19 |
| CN102417540A (zh) | 2012-04-18 |
| EP2784093A1 (en) | 2014-10-01 |
| US20170100489A1 (en) | 2017-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014CN04482A (zh) | ||
| HRP20181364T8 (hr) | Aminotriazolopiridin, namijenjen upotrebi u liječenju upale, te njegovi farmacetski pripravci | |
| HK1211467A1 (zh) | 的形式，表達 形式的細胞，以及 複合物的治療用途 | |
| IN2014DN10889A (zh) | ||
| IL236892B (en) | A combination of an immunoconjugate and an antibody for use in medical treatment, a pharmaceutical preparation and a kit containing it | |
| HK1221178A1 (zh) | 卡博替尼劑型及其在癌症治療中的使用 | |
| EP2818483A4 (en) | MEDICINAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF CANCER | |
| MX2016004678A (es) | Composiciones para el tratamiento del cancer. | |
| PL3023788T3 (pl) | Kompozycje neoantygenów specyficznych wobec nowotworu do zastosowania w leczeniu nowotworów | |
| MX2015006234A (es) | Uso de akkermansia para tratar trastornos metabolicos. | |
| PL2532680T3 (pl) | Kompozycja medyczna do leczenia raka i/lub zapobiegania | |
| WO2013005053A3 (en) | Progenitor cells of mesodermal lineage | |
| IN2014DN09098A (zh) | ||
| EP2814509A4 (en) | ANTIBODY AGAINST INTEGRIN V6 AND USE THEREOF FOR THE TREATMENT OF CANCER | |
| EA033115B1 (ru) | АНТИТЕЛА ПРОТИВ CD38 И СЛИТЫЕ БЕЛКИ С ОСЛАБЛЕННЫМ ИНТЕРФЕРОНОМ АЛЬФА-2b | |
| IL221693A (en) | 3erbb Inhibitors for Treating Breast Cancer Triple Negative and Basal-like | |
| MX2015005963A (es) | Inhibidores heterociclicos de glutaminasa. | |
| IL237125A0 (en) | Use of preparations containing niclosamide and/or its derivatives for the treatment of solid tumors | |
| IL222382A (en) | United protein fc – 1robo and its use in the treatment of tumors | |
| EP2651443A4 (en) | ANTI-CCL25 AND ANTI-CCR9 ANTIBODIES FOR THE PREVENTION AND TREATMENT OF CANCER AND THE MIGRATION OF CANCER CELLS | |
| IN2014MN01945A (zh) | ||
| MX2012008958A (es) | Antagonista de neurogulina y usos de los mismos para el tratamiento contra el cancer. | |
| PT2699233T (pt) | Material particulado e toxina celular para utilização no tratamento de um tumor sólido | |
| NZ628433A (en) | Chitosan-derived compositions | |
| MX2015003343A (es) | Tratamiento combinado con el farmaco de interferencia de netrina-1 y el farmaco quimioterapeutico. |